Tags

Type your tag names separated by a space and hit enter

[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2005 Jun; 26(6):335-8.ZX

Abstract

OBJECTIVE

To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in acute leukemia patients and its clinical implication.

METHODS

Genomic DNA from bone marrow mononuclear cells of 143 cases of acute myeloid leukemia (AML), 25 acute lymphocytic leukemia (ALL), 2 acute hybrid leukemia (AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic myelogenous leukemia in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations.

RESULTS

Among AML patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P < 0.01). According to the FAB classification, FLT3-TKD point mutation was found in 3/53 of M(2), 3/40 of M(3), 2/23 of M(5) and 1/2 of M(6) subtypes. Two patients showed both ITD and TKD mutations. No FLT3-TDK mutation was found in 25 ALL, 2 AHL, 17 MDS and 7 CML-BC patients. Sequence analysis showed that one of the mutations occurred at codon 835 of FLT3. The substitution of the first nucleotide T for G of D835, resulted in D835Y, a missense mutation. The presence of TKD mutations was related neither to age, sex, nor to WBC counts, the marrow blast percentages, and CR rates for induction therapy. CONCLUSION The incidence of FLT3-TKD(+) is significantly lower than that of ITD mutation. FLT3-TKD mutations may occur alone or together with ITD mutation. In contrast to FLT3-ITD mutation, TKD mutations were not associated with leukocytosis or low complete remission rate.

Authors+Show Affiliations

State Key Laboratory of Experimental Hematology, Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

16185475

Citation

Wang, Li-hong, et al. "[Detection of Point Mutation at Second Tyrosine Kinase Domain of FLT3 Gene in Acute Myeloid Leukemia]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 26, no. 6, 2005, pp. 335-8.
Wang LH, Wang M, Zhou CL, et al. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(6):335-8.
Wang, L. H., Wang, M., Zhou, C. L., Chen, S., Zhang, X. W., Xing, H. Y., & Wang, J. X. (2005). [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 26(6), 335-8.
Wang LH, et al. [Detection of Point Mutation at Second Tyrosine Kinase Domain of FLT3 Gene in Acute Myeloid Leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(6):335-8. PubMed PMID: 16185475.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. AU - Wang,Li-hong, AU - Wang,Min, AU - Zhou,Chun-lin, AU - Chen,Sen, AU - Zhang,Xin-wei, AU - Xing,Hai-yan, AU - Wang,Jian-xiang, PY - 2005/9/28/pubmed PY - 2009/5/8/medline PY - 2005/9/28/entrez SP - 335 EP - 8 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 26 IS - 6 N2 - OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in acute leukemia patients and its clinical implication. METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of acute myeloid leukemia (AML), 25 acute lymphocytic leukemia (ALL), 2 acute hybrid leukemia (AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic myelogenous leukemia in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations. RESULTS: Among AML patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P < 0.01). According to the FAB classification, FLT3-TKD point mutation was found in 3/53 of M(2), 3/40 of M(3), 2/23 of M(5) and 1/2 of M(6) subtypes. Two patients showed both ITD and TKD mutations. No FLT3-TDK mutation was found in 25 ALL, 2 AHL, 17 MDS and 7 CML-BC patients. Sequence analysis showed that one of the mutations occurred at codon 835 of FLT3. The substitution of the first nucleotide T for G of D835, resulted in D835Y, a missense mutation. The presence of TKD mutations was related neither to age, sex, nor to WBC counts, the marrow blast percentages, and CR rates for induction therapy. CONCLUSION The incidence of FLT3-TKD(+) is significantly lower than that of ITD mutation. FLT3-TKD mutations may occur alone or together with ITD mutation. In contrast to FLT3-ITD mutation, TKD mutations were not associated with leukocytosis or low complete remission rate. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/16185475/[Detection_of_point_mutation_at_second_tyrosine_kinase_domain_of_FLT3_gene_in_acute_myeloid_leukemia]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-2727&amp;year=2005&amp;vol=26&amp;issue=6&amp;fpage=335 DB - PRIME DP - Unbound Medicine ER -